CASI Pharmaceuticals Inc CASIF
News
Trading Information
- Previous Close Price
- $0.10
- Day Range
- $0.10–0.12
- 52-Week Range
- $0.05–1.89
- Bid/Ask
- $0.06 / $0.18
- Shares Outstanding
- 20.56M
- Market Cap
- $2.06M
- Volume/Avg
- 1,840 / 2,520
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.10
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 214
Competitors
Valuation
|
Metric
|
CASIF
|
PFE
|
|---|---|---|
Price/Earnings (Normalized) | — | 9.98 |
Price/Book Value | — | 2.04 |
Price/Sales | 0.10 | 2.73 |
Price/Cash Flow | — | 11.31 |
Price/Earnings
CASIF
PFE
Financial Strength
|
Metric
|
CASIF
|
PFE
|
|---|---|---|
Quick Ratio | 0.11 | 0.85 |
Current Ratio | 0.15 | 1.27 |
Interest Coverage | −22.75 | 2.36 |
Quick Ratio
CASIF
PFE
Profitability
|
Metric
|
CASIF
|
PFE
|
|---|---|---|
Return on Assets (Normalized) | −171.67% | 8.46% |
Return on Equity (Normalized) | — | 19.70% |
Return on Invested Capital (Normalized) | — | 12.66% |
Return on Assets
CASIF
PFE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#?DcsMy | LOCK|<W$^ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|c#cM!> | LOCK|&>NxN | $83B | |||
| Moderna Inc
MRNA
| LOCK|R@hwBp% | LOCK|@K | $81B | |||
| argenx SE ADR
ARGX
| LOCK|RLm&Rn | LOCK|WR^ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<!c!?>& | LOCK|vW | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!pnlNM | LOCK|>!?Y | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|G@<!GT< | LOCK|zZqH | $28B | |||
| Incyte Corp
INCY
| LOCK|@HVR#T | LOCK|>K< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|PYL$&jX | LOCK|!>Q | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|dzmThW | LOCK|?v% | $14B |
United States